首页 > 最新文献

Journal of Pharmacy Technology最新文献

英文 中文
Prevalence of Opioid Use in Nursing Homes Over the Last Decade: A Systematic Literature Review 过去十年养老院使用阿片类药物的普遍性:系统性文献综述
IF 1 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-12-23 DOI: 10.1177/87551225231217903
Astrid Marie Sant, Stephanie Portelli, Clive Ballard, Maria Bezzina-Xuereb, Charles Scerri, Janet Sultana
Background: Despite global concerns of an opioid epidemic, there is no systematic literature review on how frequently these drugs are used in nursing home (NH) populations, including those living with dementia. Objective: This systematic review aims to describe the prevalence and incidence of opioid use in NHs. A secondary objective is to describe the use of these drugs in a subset of NH residents, namely among persons living with dementia. Methods: A systematic literature review was carried out using MEDLINE and Scopus (PROSPERO registration number CRD42021254210). Screening of title and abstract was carried out by 2 persons independently for studies published between January 1, 2011 and May 19, 2021. The main outcomes were annual prevalence, period prevalence, and duration of opioid use. Results: From a total of 178 identified studies, 29 were considered eligible for inclusion. The annual prevalence of any opioid use among all NH residents without any selection criteria ranged from 6.3% to 50% with a median annual prevalence of 22.9% (Q25-Q75: 19.5%-30.2%), based on 17 studies. Five studies measured the annual prevalence in NH residents living with dementia, finding that this ranged from 10% to 39.6%. Conclusions: More evidence is needed quantifying opioid use in NH, especially among persons living with dementia. Given that opioid use in NH is still a problem, implementation of a pain management protocol in NH or nationally would help improve clinical outcomes.
背景:尽管全球都在关注阿片类药物的流行问题,但目前还没有系统性的文献综述来说明此类药物在养老院(NH)人群(包括痴呆症患者)中的使用频率。目的:本系统综述旨在描述阿片类药物在养老院中的使用率和发生率。其次是描述这类药物在养老院居民(即痴呆症患者)中的使用情况。研究方法:使用 MEDLINE 和 Scopus(PROSPERO 注册号 CRD42021254210)进行系统性文献综述。由两人独立对 2011 年 1 月 1 日至 2021 年 5 月 19 日期间发表的研究进行标题和摘要筛选。主要结果为阿片类药物使用的年度流行率、期间流行率和持续时间。结果:在已确定的 178 项研究中,有 29 项符合纳入条件。根据 17 项研究,在没有任何选择标准的情况下,所有北卡罗来纳州居民使用任何阿片类药物的年度流行率介于 6.3% 到 50% 之间,年度流行率中位数为 22.9%(Q25-Q75:19.5%-30.2%)。五项研究测量了患有痴呆症的国家卫生院居民的年度患病率,结果发现患病率从 10% 到 39.6% 不等。结论:需要更多证据来量化北卡罗来纳州阿片类药物的使用情况,尤其是在痴呆症患者中的使用情况。鉴于在新罕布什尔州阿片类药物的使用仍是一个问题,在新罕布什尔州或全国范围内实施疼痛管理协议将有助于改善临床效果。
{"title":"Prevalence of Opioid Use in Nursing Homes Over the Last Decade: A Systematic Literature Review","authors":"Astrid Marie Sant, Stephanie Portelli, Clive Ballard, Maria Bezzina-Xuereb, Charles Scerri, Janet Sultana","doi":"10.1177/87551225231217903","DOIUrl":"https://doi.org/10.1177/87551225231217903","url":null,"abstract":"Background: Despite global concerns of an opioid epidemic, there is no systematic literature review on how frequently these drugs are used in nursing home (NH) populations, including those living with dementia. Objective: This systematic review aims to describe the prevalence and incidence of opioid use in NHs. A secondary objective is to describe the use of these drugs in a subset of NH residents, namely among persons living with dementia. Methods: A systematic literature review was carried out using MEDLINE and Scopus (PROSPERO registration number CRD42021254210). Screening of title and abstract was carried out by 2 persons independently for studies published between January 1, 2011 and May 19, 2021. The main outcomes were annual prevalence, period prevalence, and duration of opioid use. Results: From a total of 178 identified studies, 29 were considered eligible for inclusion. The annual prevalence of any opioid use among all NH residents without any selection criteria ranged from 6.3% to 50% with a median annual prevalence of 22.9% (Q25-Q75: 19.5%-30.2%), based on 17 studies. Five studies measured the annual prevalence in NH residents living with dementia, finding that this ranged from 10% to 39.6%. Conclusions: More evidence is needed quantifying opioid use in NH, especially among persons living with dementia. Given that opioid use in NH is still a problem, implementation of a pain management protocol in NH or nationally would help improve clinical outcomes.","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2023-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139162757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of Gabapentin and Pregabalin Use in Hospitalized Patients With Decreased Kidney Function 评估肾功能减退的住院患者使用加巴喷丁和普瑞巴林的情况
IF 1 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-12-18 DOI: 10.1177/87551225231217906
Gwendolyn M. Knowles, Grace E. LaFleur, Mariann D. Churchwell
Background: Gabapentin and pregabalin are well-tolerated medications primarily cleared by the kidney. Patients receiving higher gabapentinoid doses with decreased kidney function may be at an increased risk of adverse effects (AEs), but limited evidence exists evaluating gabapentinoid dosing and AEs in this population. Objective: To determine whether patients with decreased creatinine clearance (CrCl) experienced increased frequency of AEs related to gabapentinoid dose at hospital admission. Methods: Single-center retrospective cohort study in adults with a gabapentinoid prescription and serum creatinine measurement documented on hospital admission. The primary outcome was the appropriateness of gabapentinoid prescription based on CrCl (stratified by CrCl ≥60 mL/min, <60 mL/min, 15-29 mL/min, and <15 mL/min) at admission. Secondary outcomes included the incidence of AEs related to gabapentinoids and concomitant opioid and psychiatric prescriptions. Results: A total of 286 patients were included in this study (gabapentin n = 234, pregabalin n = 52). Patients with a CrCl <60 mL/min and doses above the manufacturer’s recommendation were prescribed gabapentin (34%) and pregabalin (22.7%). For patients with a CrCl of 15 to 29 mL/min and <15 mL/min groups, inappropriately high doses were prescribed for gabapentin (48.8%) and pregabalin (45%). A significant increase in recorded falls ( P = 0.029) was identified in patients with a CrCl <60 mL/min. Concomitant opioid and psychiatric medications contributed to a higher prevalence of AEs regardless of CrCl. Conclusions: Patients with a CrCl <60 mL/min were frequently prescribed inappropriately high doses of gabapentinoids. The relationship between gabapentinoid dosing, kidney function, and the incidence of gabapentinoid-related AEs at hospital admission requires larger, multicentre studies.
背景:加巴喷丁和普瑞巴林是耐受性良好的药物,主要由肾脏清除。接受较高剂量加巴喷丁且肾功能下降的患者发生不良反应(AEs)的风险可能会增加,但目前评估这类人群加巴喷丁剂量和 AEs 的证据有限。目的确定肌酐清除率(CrCl)降低的患者在入院时是否会出现与加巴喷丁胺剂量相关的更高频率的不良反应。方法: 单中心回顾性队列研究单中心回顾性队列研究,对象为开具加巴喷丁类药物处方且入院时有血清肌酐测量记录的成人。主要结果是根据入院时的 CrCl(按 CrCl ≥60 mL/min、<60 mL/min、15-29 mL/min 和 <15 mL/min 分层)确定加巴喷丁胺处方的适当性。次要结果包括与加巴喷丁类药物相关的AEs发生率以及阿片类药物和精神科处方的并发症发生率。研究结果本研究共纳入 286 例患者(加巴喷丁 n = 234 例,普瑞巴林 n = 52 例)。CrCl<60毫升/分钟且剂量高于制造商推荐值的患者被处方加巴喷丁(34%)和普瑞巴林(22.7%)。在 CrCl 为 15 至 29 毫升/分钟和小于 15 毫升/分钟的患者组中,加巴喷丁(48.8%)和普瑞巴林(45%)的处方剂量过高。在 CrCl <60 毫升/分钟的患者中,记录到的跌倒次数明显增加 ( P = 0.029)。同时服用阿片类药物和精神类药物会导致更高的 AEs 发生率,与 CrCl 无关。结论CrCl<60毫升/分钟的患者经常被处方不适当的高剂量加巴喷丁类药物。加巴喷丁类药物剂量、肾功能和入院时加巴喷丁类药物相关不良反应发生率之间的关系需要进行更大规模的多中心研究。
{"title":"Evaluation of Gabapentin and Pregabalin Use in Hospitalized Patients With Decreased Kidney Function","authors":"Gwendolyn M. Knowles, Grace E. LaFleur, Mariann D. Churchwell","doi":"10.1177/87551225231217906","DOIUrl":"https://doi.org/10.1177/87551225231217906","url":null,"abstract":"Background: Gabapentin and pregabalin are well-tolerated medications primarily cleared by the kidney. Patients receiving higher gabapentinoid doses with decreased kidney function may be at an increased risk of adverse effects (AEs), but limited evidence exists evaluating gabapentinoid dosing and AEs in this population. Objective: To determine whether patients with decreased creatinine clearance (CrCl) experienced increased frequency of AEs related to gabapentinoid dose at hospital admission. Methods: Single-center retrospective cohort study in adults with a gabapentinoid prescription and serum creatinine measurement documented on hospital admission. The primary outcome was the appropriateness of gabapentinoid prescription based on CrCl (stratified by CrCl ≥60 mL/min, <60 mL/min, 15-29 mL/min, and <15 mL/min) at admission. Secondary outcomes included the incidence of AEs related to gabapentinoids and concomitant opioid and psychiatric prescriptions. Results: A total of 286 patients were included in this study (gabapentin n = 234, pregabalin n = 52). Patients with a CrCl <60 mL/min and doses above the manufacturer’s recommendation were prescribed gabapentin (34%) and pregabalin (22.7%). For patients with a CrCl of 15 to 29 mL/min and <15 mL/min groups, inappropriately high doses were prescribed for gabapentin (48.8%) and pregabalin (45%). A significant increase in recorded falls ( P = 0.029) was identified in patients with a CrCl <60 mL/min. Concomitant opioid and psychiatric medications contributed to a higher prevalence of AEs regardless of CrCl. Conclusions: Patients with a CrCl <60 mL/min were frequently prescribed inappropriately high doses of gabapentinoids. The relationship between gabapentinoid dosing, kidney function, and the incidence of gabapentinoid-related AEs at hospital admission requires larger, multicentre studies.","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2023-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138964341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nivolumab Safety in Renal Cell Carcinoma: A Case Report 尼妥珠单抗在肾细胞癌中的安全性:病例报告
IF 1 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-12-15 DOI: 10.1177/87551225231218164
James Debono, D. Balzan, John-Joseph Borg, Stephen Falzon, Dania al-Haddad, Benjamin Micallef, Janet Sultana
Nivolumab is used to treat several different types of cancers. Although it is generally considered to be effective and well-tolerated, it has been associated with adverse effects requiring discontinuation of treatment, like many other drugs used for cancer. A 70-year-old male was switched from sunitinib to nivolumab for renal cell carcinoma. The patient developed persistent hypothyroidism, onycholysis, and pneumonitis at nivolumab cycle 6, 10, and 11, respectively. Using the Naranjo causality method, the likelihood of causality was deemed “probable” for pneumonitis and hypothyroidism and “possible” for onycholysis. Nivolumab was eventually discontinued due to disease progression, rather than safety concerns. Eudravigilance, the European pharmacovigilance database, was searched for all nivolumab-related individual case safety reports from Malta, up to September 4, 2023. Six reports were identified in Malta, although the 3 events identified in this case report were not reported, suggesting under-reporting in Malta. This case report identified an uncommon nivolumab adverse drug reaction (ADR), onycholysis and showed how, despite the occurrence of 3 ADRs, it was its lack of efficacy rather than its safety which led to its discontinuation in this particular patient.
Nivolumab 用于治疗多种不同类型的癌症。虽然人们普遍认为它有效且耐受性良好,但与许多其他治疗癌症的药物一样,它也与需要中断治疗的不良反应有关。一名 70 岁的男性患者因患肾细胞癌从舒尼替尼转为使用 nivolumab。该患者分别在 nivolumab 第 6、10 和 11 周期出现了持续性甲状腺功能减退、甲状腺肿和肺炎。采用纳兰霍因果关系法,认为肺炎和甲状腺功能减退的因果关系为 "可能",甲状腺肿大的因果关系为 "可能"。Nivolumab最终因疾病进展而停药,而非安全性问题。在欧洲药物警戒数据库 Eudravigilance 中搜索了截至 2023 年 9 月 4 日马耳他所有与尼夫单抗相关的个体病例安全报告。在马耳他发现了六份报告,但本病例报告中发现的三起事件并未报告,这表明马耳他的报告不足。本病例报告确定了一种不常见的 nivolumab 药物不良反应 (ADR)--甲状旁腺溶解症,并说明了尽管发生了 3 例 ADR,但导致该特定患者停药的原因是其缺乏疗效而非安全性。
{"title":"Nivolumab Safety in Renal Cell Carcinoma: A Case Report","authors":"James Debono, D. Balzan, John-Joseph Borg, Stephen Falzon, Dania al-Haddad, Benjamin Micallef, Janet Sultana","doi":"10.1177/87551225231218164","DOIUrl":"https://doi.org/10.1177/87551225231218164","url":null,"abstract":"Nivolumab is used to treat several different types of cancers. Although it is generally considered to be effective and well-tolerated, it has been associated with adverse effects requiring discontinuation of treatment, like many other drugs used for cancer. A 70-year-old male was switched from sunitinib to nivolumab for renal cell carcinoma. The patient developed persistent hypothyroidism, onycholysis, and pneumonitis at nivolumab cycle 6, 10, and 11, respectively. Using the Naranjo causality method, the likelihood of causality was deemed “probable” for pneumonitis and hypothyroidism and “possible” for onycholysis. Nivolumab was eventually discontinued due to disease progression, rather than safety concerns. Eudravigilance, the European pharmacovigilance database, was searched for all nivolumab-related individual case safety reports from Malta, up to September 4, 2023. Six reports were identified in Malta, although the 3 events identified in this case report were not reported, suggesting under-reporting in Malta. This case report identified an uncommon nivolumab adverse drug reaction (ADR), onycholysis and showed how, despite the occurrence of 3 ADRs, it was its lack of efficacy rather than its safety which led to its discontinuation in this particular patient.","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2023-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139000458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Implementation and Evaluation of Weight-Based Vasopressors in Intensive Care Units 在重症监护病房实施和评估基于体重的血管加压器
IF 1 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-12-15 DOI: 10.1177/87551225231217905
Laurie DeMillard, Michael Thuyns
Background: Vasopressors, including norepinephrine, epinephrine, and phenylephrine are commonly used to maintain mean arterial pressure (MAP) in critically ill patients. Despite their frequent use, the optimal dosing strategy for vasopressors remains understudied. Objective: The purpose of this study is to evaluate the implementation of a weight-based (WB) dosing strategy using ideal body weight compared to a non-weight-based (NWB) dosing strategy for vasopressors in critically ill patients. Methods: This is a retrospective chart review of patients admitted to intensive care units receiving vasopressor medications for greater than or equal to 4 hours. Patients received either an NWB or a WB vasopressor dosing strategy. The primary endpoint was the time to achieve goal MAP. Results: This study included 153 patients in the NWB vasopressor dosing group and 183 in the WB dosing group. The median time to achieve goal MAP in the NWB group was 24 minutes versus 21 minutes in the WB group ( P = 0.1713). There were no significant differences in secondary outcomes including number of vasoactive agents required, hospital length of stay, and duration of mechanical ventilation. Subgroup analysis of patients with extremes of body mass index did not show a difference in time to achieve goal MAP. In a subgroup analysis of patients with septic shock, a higher percentage of patients in the WB group received corticosteroids than the NWB group patients (14% vs. 54%; P ≤ 0.001). Conclusion and relevance: There was no difference in time to achieve goal MAP when using a WB or NWB vasopressor dosing approach. Institutions should employ a consistent dosing strategy for vasopressors with either an NWB or WB approach.
背景:血管加压药(包括去甲肾上腺素、肾上腺素和苯肾上腺素)常用于维持重症患者的平均动脉压(MAP)。尽管血管加压药使用频繁,但其最佳剂量策略仍未得到充分研究。研究目的本研究旨在评估重症患者使用血管加压药时,基于体重(WB)的理想体重给药策略与非基于体重(NWB)的给药策略的实施情况。方法:这是对重症监护病房收治的接受血管加压药物治疗超过或等于 4 小时的患者进行的回顾性病历审查。患者接受的是 NWB 或 WB 血管加压药剂量策略。主要终点是达到目标 MAP 的时间。研究结果该研究的 NWB 加压剂给药组和 WB 给药组分别有 153 名和 183 名患者。NWB 组达到目标 MAP 的中位时间为 24 分钟,而 WB 组为 21 分钟(P = 0.1713)。在次要结果方面,包括所需血管活性药物的数量、住院时间和机械通气持续时间,两组之间没有明显差异。对体重指数极端的患者进行的亚组分析表明,达到目标 MAP 的时间没有差异。在对脓毒性休克患者进行的亚组分析中,WB 组患者接受皮质类固醇治疗的比例高于 NWB 组患者(14% 对 54%;P ≤ 0.001)。结论和意义:使用 WB 或 NWB 血管抑制剂剂量方法时,达到目标 MAP 的时间没有差异。医疗机构应采用一致的剂量策略,使用 NWB 或 WB 法使用血管加压药。
{"title":"Implementation and Evaluation of Weight-Based Vasopressors in Intensive Care Units","authors":"Laurie DeMillard, Michael Thuyns","doi":"10.1177/87551225231217905","DOIUrl":"https://doi.org/10.1177/87551225231217905","url":null,"abstract":"Background: Vasopressors, including norepinephrine, epinephrine, and phenylephrine are commonly used to maintain mean arterial pressure (MAP) in critically ill patients. Despite their frequent use, the optimal dosing strategy for vasopressors remains understudied. Objective: The purpose of this study is to evaluate the implementation of a weight-based (WB) dosing strategy using ideal body weight compared to a non-weight-based (NWB) dosing strategy for vasopressors in critically ill patients. Methods: This is a retrospective chart review of patients admitted to intensive care units receiving vasopressor medications for greater than or equal to 4 hours. Patients received either an NWB or a WB vasopressor dosing strategy. The primary endpoint was the time to achieve goal MAP. Results: This study included 153 patients in the NWB vasopressor dosing group and 183 in the WB dosing group. The median time to achieve goal MAP in the NWB group was 24 minutes versus 21 minutes in the WB group ( P = 0.1713). There were no significant differences in secondary outcomes including number of vasoactive agents required, hospital length of stay, and duration of mechanical ventilation. Subgroup analysis of patients with extremes of body mass index did not show a difference in time to achieve goal MAP. In a subgroup analysis of patients with septic shock, a higher percentage of patients in the WB group received corticosteroids than the NWB group patients (14% vs. 54%; P ≤ 0.001). Conclusion and relevance: There was no difference in time to achieve goal MAP when using a WB or NWB vasopressor dosing approach. Institutions should employ a consistent dosing strategy for vasopressors with either an NWB or WB approach.","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2023-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139000712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Appendicitis: A Hidden Danger of GLP-1 Receptor Agonists? 阑尾炎:GLP-1 受体激动剂的隐患?
IF 1 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-12-07 DOI: 10.1177/87551225231216638
Sarah Casella, Katelyn Galli
Introduction: While glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have become increasingly prescribed, use is often inhibited by the gastrointestinal adverse effects that patients must endure. Nausea, vomiting, and cholelithiasis are most commonly associated with use, with little to no data or labeling reflecting risk of appendicitis or associated symptoms. Appendicitis etiology is theorized to develop secondary to obstruction of the vermiform via infection or fecalith causing an increase in intraluminal pressure. It is hypothesized that given the aforementioned gastrointestinal effects associated with GLP-1 RAs, patients taking such agents may be more at risk for developing this acute condition. Patient Case: We describe a case of a 48-year-old woman who presented to the emergency department several months after being initiated on Ozempic (semaglutide). This report aims to analyze the potential secondary adverse effects that may result from GLP-1 RA use. Her examination was positive for focal abdominal tenderness and leukocytosis along with imaging suggestive of appendicitis. Her acute condition ultimately required an appendectomy. Discussion: While minimal data are available to suggest significant causation between GLP-1 RAs and appendicitis, a literature and database search revealed that instances may be more common than previously thought. Conclusion: Trial results and adverse event reporting systems report an infrequent incidence in patients using these medications, but this report aims to contribute to the literature describing this potential adverse event.
导语:虽然胰高血糖素样肽-1受体激动剂(GLP-1 RAs)的处方越来越多,但由于患者必须忍受胃肠道不良反应,其使用往往受到抑制。恶心、呕吐和胆石症最常与使用相关,很少或没有数据或标签反映阑尾炎或相关症状的风险。阑尾炎的病因被认为是继发于蚓状阻塞,通过感染或粪便引起腔内压力增加。假设考虑到上述与GLP-1 RAs相关的胃肠道效应,服用此类药物的患者可能更容易发生这种急性疾病。患者病例:我们描述了一例48岁的妇女谁提出了几个月后,开始Ozempic(西马鲁肽)急诊科。本报告旨在分析GLP-1 RA使用可能导致的潜在继发性不良反应。她的检查呈局灶性腹部压痛和白细胞增多阳性,影像学提示阑尾炎。她的急性病情最终需要阑尾切除术。讨论:虽然很少有数据表明GLP-1 RAs与阑尾炎之间存在显著的因果关系,但文献和数据库搜索显示,这种情况可能比以前认为的更常见。结论:试验结果和不良事件报告系统报告了使用这些药物的患者的罕见发生率,但本报告旨在为描述这种潜在不良事件的文献做出贡献。
{"title":"Appendicitis: A Hidden Danger of GLP-1 Receptor Agonists?","authors":"Sarah Casella, Katelyn Galli","doi":"10.1177/87551225231216638","DOIUrl":"https://doi.org/10.1177/87551225231216638","url":null,"abstract":"Introduction: While glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have become increasingly prescribed, use is often inhibited by the gastrointestinal adverse effects that patients must endure. Nausea, vomiting, and cholelithiasis are most commonly associated with use, with little to no data or labeling reflecting risk of appendicitis or associated symptoms. Appendicitis etiology is theorized to develop secondary to obstruction of the vermiform via infection or fecalith causing an increase in intraluminal pressure. It is hypothesized that given the aforementioned gastrointestinal effects associated with GLP-1 RAs, patients taking such agents may be more at risk for developing this acute condition. Patient Case: We describe a case of a 48-year-old woman who presented to the emergency department several months after being initiated on Ozempic (semaglutide). This report aims to analyze the potential secondary adverse effects that may result from GLP-1 RA use. Her examination was positive for focal abdominal tenderness and leukocytosis along with imaging suggestive of appendicitis. Her acute condition ultimately required an appendectomy. Discussion: While minimal data are available to suggest significant causation between GLP-1 RAs and appendicitis, a literature and database search revealed that instances may be more common than previously thought. Conclusion: Trial results and adverse event reporting systems report an infrequent incidence in patients using these medications, but this report aims to contribute to the literature describing this potential adverse event.","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2023-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138591284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Drug Utilization Evaluation Study of Ciprofloxacin Use and Adverse Events Occurrence: Role of Community Pharmacists 环丙沙星使用和不良事件发生的药物利用评价研究:社区药剂师的作用
IF 1 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-12-06 DOI: 10.1177/87551225231216328
Gaidaa M. Dogheim, Rehab H. Werida
Background: Antimicrobial resistance is a global health crisis threatening optimal management of infectious diseases. Ciprofloxacin is a widely used fluoroquinolone in various disease conditions. Resistance against ciprofloxacin is increasing, leading to nonoptimal management of patients. Thus, the aim of this study was to assess ciprofloxacin use in the community setting in terms of appropriate prescribing, dosing, frequency, and duration of use. Methods: A cross-sectional, retrospective study was conducted by community pharmacists in 5 community pharmacies in Egypt from September 2021 to February 2022. Patients prescribed oral ciprofloxacin during the period of the study were included. Data on demographics, indications for ciprofloxacin, dosing regimen, adverse events, and drug interactions were collected. Results: A total of 151 patients’ record indicated for ciprofloxacin were included in the study, of whom 44.4% were men and 55.6% were women who were neither pregnant nor lactating. Based on international guidelines, 96.69% ciprofloxacin prescriptions were appropriate; 96.03% contained correct ciprofloxacin dosing whereas 3.97% were overdose. A total of 90. 73% had correct frequency of administration and 96.03% records had correct durations. Only 1.99% of patients were ≤18 years of age, which is an absolute contraindication. Interacting drugs with ciprofloxacin were 28.5% with acetaminophen, 31.1% with ibuprofen, 16.6% with antacids, 21.2% with chlorpheniramine, and 7.9% with prednisolone. Adverse events included 1.32% hypoglycemia, 0.66% hyperglycemia, 3.97% tendinitis, and 2.65% QTc (heart rate–corrected QT interval) prolongation. Conclusion and relevance: Ciprofloxacin use in community pharmacies is appropriate according to international guidelines. Ongoing drug utilization evaluation is necessary to ensure rational drug use, which in turn can decrease resistance rates.
背景:抗菌素耐药性是威胁传染病最佳管理的全球性健康危机。环丙沙星是一种广泛应用于各种疾病的氟喹诺酮类药物。对环丙沙星的耐药性正在增加,导致患者管理不善。因此,本研究的目的是评估环丙沙星在社区环境中的使用情况,包括适当的处方、剂量、频率和使用时间。方法:对埃及5家社区药房的社区药师于2021年9月至2022年2月进行横断面回顾性研究。研究期间服用口服环丙沙星的患者也被纳入研究范围。收集了人口统计学、环丙沙星适应症、给药方案、不良事件和药物相互作用的数据。结果:共纳入151例使用环丙沙星的患者,其中44.4%为男性,55.6%为非妊娠期和哺乳期女性。根据国际指南,环丙沙星处方合规性为96.69%;环丙沙星剂量正确的占96.03%,过量的占3.97%。总共90个。73%的给药频率正确,96.03%的给药时间正确。年龄≤18岁的患者仅占1.99%,为绝对禁忌症。环丙沙星与对乙酰氨基酚的相互作用占28.5%,与布洛芬的相互作用占31.1%,与抗酸药的相互作用占16.6%,与氯苯那敏的相互作用占21.2%,与强的松龙的相互作用占7.9%。不良事件包括1.32%的低血糖,0.66%的高血糖,3.97%的肌腱炎和2.65%的QTc(心率校正QT间期)延长。结论及意义:根据国际指南,环丙沙星在社区药房的使用是适当的。持续的药物利用评价是必要的,以确保合理用药,从而降低耐药率。
{"title":"Drug Utilization Evaluation Study of Ciprofloxacin Use and Adverse Events Occurrence: Role of Community Pharmacists","authors":"Gaidaa M. Dogheim, Rehab H. Werida","doi":"10.1177/87551225231216328","DOIUrl":"https://doi.org/10.1177/87551225231216328","url":null,"abstract":"Background: Antimicrobial resistance is a global health crisis threatening optimal management of infectious diseases. Ciprofloxacin is a widely used fluoroquinolone in various disease conditions. Resistance against ciprofloxacin is increasing, leading to nonoptimal management of patients. Thus, the aim of this study was to assess ciprofloxacin use in the community setting in terms of appropriate prescribing, dosing, frequency, and duration of use. Methods: A cross-sectional, retrospective study was conducted by community pharmacists in 5 community pharmacies in Egypt from September 2021 to February 2022. Patients prescribed oral ciprofloxacin during the period of the study were included. Data on demographics, indications for ciprofloxacin, dosing regimen, adverse events, and drug interactions were collected. Results: A total of 151 patients’ record indicated for ciprofloxacin were included in the study, of whom 44.4% were men and 55.6% were women who were neither pregnant nor lactating. Based on international guidelines, 96.69% ciprofloxacin prescriptions were appropriate; 96.03% contained correct ciprofloxacin dosing whereas 3.97% were overdose. A total of 90. 73% had correct frequency of administration and 96.03% records had correct durations. Only 1.99% of patients were ≤18 years of age, which is an absolute contraindication. Interacting drugs with ciprofloxacin were 28.5% with acetaminophen, 31.1% with ibuprofen, 16.6% with antacids, 21.2% with chlorpheniramine, and 7.9% with prednisolone. Adverse events included 1.32% hypoglycemia, 0.66% hyperglycemia, 3.97% tendinitis, and 2.65% QTc (heart rate–corrected QT interval) prolongation. Conclusion and relevance: Ciprofloxacin use in community pharmacies is appropriate according to international guidelines. Ongoing drug utilization evaluation is necessary to ensure rational drug use, which in turn can decrease resistance rates.","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2023-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138596916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism in Obesity. 直接口服抗凝剂治疗肥胖症静脉血栓栓塞。
IF 1.1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2023-12-01 Epub Date: 2023-09-04 DOI: 10.1177/87551225231196748
Quinn Hattaway, Jessica A Starr, Nathan A Pinner

Background: Direct oral anticoagulants (DOACs) are known to have similar efficacy with a decreased risk of bleeding when compared to warfarin for the treatment of venous thromboembolism (VTE). In patients with obesity, there are limited data regarding the safety and efficacy of DOACs. Despite concerns for both under- and over-dosing patients with extremes of body weight, there are no dose adjustment recommendations in the package inserts for any of the DOACs. Objective: To evaluate the safety and efficacy of DOACs versus warfarin for the treatment of VTE in patients with obesity. Methods: This single-center, retrospective cohort study included obese patients initiated on DOAC or warfarin therapy for VTE from January 2015 to January 2022. Patients with cancer, hypercoagulable disorders, end-stage kidney disease, or pregnancy were excluded. The primary endpoint was VTE recurrence. Secondary endpoints included major and minor bleeding. Results: A total of 120 patients met criteria for inclusion. Ninety-two received DOAC therapy and 28 received warfarin. The primary endpoint occurred in 4 patients in the DOAC group and 3 patients in the warfarin group (P = 0.35). Major bleeding occurred in 2 patients. Minor bleeding events occurred in 10 (8.33%) patients. Of those, 6 (6.5%) events occurred in patients receiving a DOAC and 4 (14.3%) events occurred in patients receiving warfarin (P = 0.28). Limitations of this study include the retrospective single-center study design. Conclusions: There was a comparable risk of bleeding and recurrent VTE between DOACs and warfarin in patients initiated on therapy for VTE.

背景:与华法林相比,直接口服抗凝剂(DOACs)治疗静脉血栓栓塞(VTE)的疗效相似,出血风险降低。在肥胖患者中,关于doac的安全性和有效性的数据有限。尽管对体重极端的患者的剂量不足和过量都有担忧,但在任何doac的包装说明书中都没有剂量调整建议。目的:评价DOACs与华法林治疗肥胖患者静脉血栓栓塞的安全性和有效性。方法:这项单中心、回顾性队列研究纳入了2015年1月至2022年1月期间接受DOAC或华法林治疗静脉血栓栓塞的肥胖患者。排除癌症、高凝障碍、终末期肾病或妊娠患者。主要终点为静脉血栓栓塞复发。次要终点包括大出血和小出血。结果:共有120例患者符合纳入标准。92例接受DOAC治疗,28例接受华法林治疗。DOAC组4例患者出现主要终点,华法林组3例患者出现主要终点(P = 0.35)。2例发生大出血。10例(8.33%)发生轻微出血。其中,6例(6.5%)事件发生在接受DOAC的患者中,4例(14.3%)事件发生在接受华法林的患者中(P = 0.28)。本研究的局限性包括回顾性单中心研究设计。结论:在开始治疗静脉血栓栓塞的患者中,DOACs和华法林之间出血和复发性静脉血栓栓塞的风险相当。
{"title":"Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism in Obesity.","authors":"Quinn Hattaway, Jessica A Starr, Nathan A Pinner","doi":"10.1177/87551225231196748","DOIUrl":"10.1177/87551225231196748","url":null,"abstract":"<p><p><b>Background:</b> Direct oral anticoagulants (DOACs) are known to have similar efficacy with a decreased risk of bleeding when compared to warfarin for the treatment of venous thromboembolism (VTE). In patients with obesity, there are limited data regarding the safety and efficacy of DOACs. Despite concerns for both under- and over-dosing patients with extremes of body weight, there are no dose adjustment recommendations in the package inserts for any of the DOACs. <b>Objective:</b> To evaluate the safety and efficacy of DOACs versus warfarin for the treatment of VTE in patients with obesity. <b>Methods:</b> This single-center, retrospective cohort study included obese patients initiated on DOAC or warfarin therapy for VTE from January 2015 to January 2022. Patients with cancer, hypercoagulable disorders, end-stage kidney disease, or pregnancy were excluded. The primary endpoint was VTE recurrence. Secondary endpoints included major and minor bleeding. <b>Results:</b> A total of 120 patients met criteria for inclusion. Ninety-two received DOAC therapy and 28 received warfarin. The primary endpoint occurred in 4 patients in the DOAC group and 3 patients in the warfarin group (<i>P</i> = 0.35). Major bleeding occurred in 2 patients. Minor bleeding events occurred in 10 (8.33%) patients. Of those, 6 (6.5%) events occurred in patients receiving a DOAC and 4 (14.3%) events occurred in patients receiving warfarin (<i>P</i> = 0.28). Limitations of this study include the retrospective single-center study design. <b>Conclusions:</b> There was a comparable risk of bleeding and recurrent VTE between DOACs and warfarin in patients initiated on therapy for VTE.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640866/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90400658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tigecycline and Hypoglycemia, When and How? 替加环素与低血糖,何时发生,如何发生?
IF 1 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-11-18 DOI: 10.1177/87551225231211737
Hakeam A. Hakeam, Khadija A. Sarkhi, Alla Iansavichene
Objective: To describe the clinical characteristics of hypoglycemia that develop with tigecycline therapy and to review and summarize the current evidence of this uncommonly occurring metabolic adverse effect of tigecycline therapy. Underlying risk factors and potential mechanisms are also discussed. Data source: A 3-phase literature search was performed. In phase 1, the Cochrane Central Register of Controlled Trials (CENTRAL) Library, MEDLINE, and Embase electronic databases were searched for hypoglycemia and tigecycline, published from inception until August 2023. In phase 2, MEDLINE was searched for tigecycline randomized controlled trials and results were manually screened for hypoglycemia. In phase 3, the US Food and Drug Administration Adverse Event Reporting System public dashboard was searched for reports on tigecycline and hypoglycemia from June 2005 until July 2023. Study selection and data extraction: Relevant English-language citations and those conducted in humans were considered. Relevance to patient care and clinical practice: Hypoglycemia of various causes is an independent mortality risk. This review raises awareness among clinicians about the possibility of hypoglycemia with tigecycline therapy. Conclusion: Data on tigecycline-related hypoglycemia are scarce. Hypoglycemia may occur at any time during tigecycline therapy and can be severe and persist for days after tigecycline cessation. Renal dysfunction or renal replacement therapy may predispose to severe hypoglycemia during tigecycline therapy. Tigecycline-related hypoglycemia may develop in patients with or without diabetes mellitus and appears independent of insulin or antidiabetic agents. Intravenous dextrose showed efficacy in the restoration of euglycemia. Studies are needed to determine whether tigecycline-related hypoglycemia is iatrogenic or spontaneous.
目的描述替加环素治疗过程中出现的低血糖症的临床特征,回顾并总结替加环素治疗过程中这种罕见代谢不良反应的现有证据。此外,还讨论了潜在的风险因素和机制。数据来源:进行了三个阶段的文献检索。在第 1 阶段,在 Cochrane 对照试验中央注册库 (CENTRAL) 图书馆、MEDLINE 和 Embase 电子数据库中检索了从开始到 2023 年 8 月发表的有关低血糖和替加环素的文献。第 2 阶段,在 MEDLINE 中检索替加环素随机对照试验,并对结果进行人工低血糖筛查。第三阶段,在美国食品和药物管理局不良事件报告系统(US Food and Drug Administration Adverse Event Reporting System public dashboard)中搜索自 2005 年 6 月至 2023 年 7 月有关替加环素和低血糖症的报告。研究选择和数据提取:考虑相关的英文引文和在人体中进行的研究。与患者护理和临床实践的相关性:各种原因导致的低血糖是一种独立的死亡风险。本综述提高了临床医生对替加环素治疗低血糖可能性的认识。结论有关替加环素相关低血糖症的数据很少。低血糖可能在替加环素治疗期间的任何时候发生,严重的低血糖可能在停用替加环素后持续数天。肾功能不全或肾脏替代疗法可能导致在替加环素治疗期间出现严重低血糖。无论患者是否患有糖尿病,都可能出现与替加环素相关的低血糖症,且与胰岛素或抗糖尿病药物无关。静脉注射葡萄糖对恢复优格血症有效。需要进行研究以确定与替加环素相关的低血糖症是先天性的还是自发性的。
{"title":"Tigecycline and Hypoglycemia, When and How?","authors":"Hakeam A. Hakeam, Khadija A. Sarkhi, Alla Iansavichene","doi":"10.1177/87551225231211737","DOIUrl":"https://doi.org/10.1177/87551225231211737","url":null,"abstract":"Objective: To describe the clinical characteristics of hypoglycemia that develop with tigecycline therapy and to review and summarize the current evidence of this uncommonly occurring metabolic adverse effect of tigecycline therapy. Underlying risk factors and potential mechanisms are also discussed. Data source: A 3-phase literature search was performed. In phase 1, the Cochrane Central Register of Controlled Trials (CENTRAL) Library, MEDLINE, and Embase electronic databases were searched for hypoglycemia and tigecycline, published from inception until August 2023. In phase 2, MEDLINE was searched for tigecycline randomized controlled trials and results were manually screened for hypoglycemia. In phase 3, the US Food and Drug Administration Adverse Event Reporting System public dashboard was searched for reports on tigecycline and hypoglycemia from June 2005 until July 2023. Study selection and data extraction: Relevant English-language citations and those conducted in humans were considered. Relevance to patient care and clinical practice: Hypoglycemia of various causes is an independent mortality risk. This review raises awareness among clinicians about the possibility of hypoglycemia with tigecycline therapy. Conclusion: Data on tigecycline-related hypoglycemia are scarce. Hypoglycemia may occur at any time during tigecycline therapy and can be severe and persist for days after tigecycline cessation. Renal dysfunction or renal replacement therapy may predispose to severe hypoglycemia during tigecycline therapy. Tigecycline-related hypoglycemia may develop in patients with or without diabetes mellitus and appears independent of insulin or antidiabetic agents. Intravenous dextrose showed efficacy in the restoration of euglycemia. Studies are needed to determine whether tigecycline-related hypoglycemia is iatrogenic or spontaneous.","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2023-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139261601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Annual Wholesale Acquisition Costs of Novel Drugs Relative to US County-Level House Prices 相对于美国县级房价的新型药物年度批发采购成本
IF 1 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-11-15 DOI: 10.1177/87551225231213259
Jessica H. Williams, Savannah Young, Kaitlyn Wallace, E. Weeda
{"title":"Annual Wholesale Acquisition Costs of Novel Drugs Relative to US County-Level House Prices","authors":"Jessica H. Williams, Savannah Young, Kaitlyn Wallace, E. Weeda","doi":"10.1177/87551225231213259","DOIUrl":"https://doi.org/10.1177/87551225231213259","url":null,"abstract":"","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2023-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139273642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of Student Pharmacist-Led Transition-of-Care Services on 30-Day Hospital Readmissions at a University Call Center. 学生药剂师领导的护理服务过渡对大学呼叫中心30天医院重新使命的影响。
IF 1.1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2023-10-01 Epub Date: 2023-07-21 DOI: 10.1177/87551225231187832
Huy Pham, Tricia Gangoo-Dookhan, Genevieve Hale, Alexandra Perez, Tina Joseph

Background: Transition of care (TOC) refers to the movement of patients between different health care settings due to changes in medical conditions and needs. Pharmacists can play an important role in TOC services as polypharmacy is a common reason for hospital readmission that costs the US taxpayers an average of $17 billion annually. Objective: The purpose of this study is to evaluate the impact of TOC telehealth services provided by pharmacy students at a university-based call center on 30-day hospital readmission. Methods: In this retrospective observational study, an electronic chart review was conducted for patients who were discharged from the hospital and received a telephone call from pharmacy students. Patients were referred to the pharmacy team from a primary care provider office. The co-primary endpoints were the number of 30-day all-cause hospital readmissions (including emergency department visits) and 30-day readmission due to initial admission diagnosis in patients who received a telephonic TOC call from a pharmacy student compared with patients who declined or were unable to be reached. Types of pharmacy-related TOC interventions provided by students were also collected. Results: A total of 84 patients were included in this study. All-cause 30-day readmission was similar between groups (13% vs 15.8%), whereas 30-day readmission due to initial admission diagnosis was much lower in the intervention group (5.9% vs 11.1%). Although a positive trend was observed in favor of the intervention group, a statistically significant difference was not observed for both 30-day all-cause readmission and 30-day readmission due to initial admission diagnosis. Medication reconciliation, adherence counseling, and lifestyle education (diet, exercise) are the most common topics discussed with the patients during TOC interventions. Conclusion: Using student pharmacists to provide postdischarge TOC calls can be a benefit to the patient and the health care team while offering pharmacy students valuable learning experience prior to graduation.

背景:护理过渡(TOC)是指由于医疗条件和需求的变化,患者在不同的医疗机构之间的流动。药剂师可以在TOC服务中发挥重要作用,因为多药治疗是重新入院的常见原因,美国纳税人每年平均为此花费170亿美元。目的:本研究的目的是评估大学呼叫中心药学系学生提供的TOC远程医疗服务对30天住院的影响。方法:在这项回顾性观察性研究中,对出院并接到药学专业学生电话的患者进行了电子病历审查。患者被转介到初级保健提供者办公室的药房团队。共同的主要终点是,与拒绝或无法联系到的患者相比,收到药学专业学生电话TOC电话的患者30天全因住院(包括急诊科就诊)和30天因初次入院诊断而再次入院的次数。还收集了学生提供的与药学相关的TOC干预措施的类型。结果:本研究共纳入84例患者。全因30天再次入院在各组之间相似(13%对15.8%),而干预组因首次入院诊断而再次入院的30天要低得多(5.9%对11.1%)。尽管观察到有利于干预组的积极趋势,30天全因再次入院和30天因首次入院诊断再次入院均未观察到统计学上的显著差异。药物调节、依从性咨询和生活方式教育(饮食、锻炼)是TOC干预期间与患者讨论的最常见的话题。结论:使用学生药剂师提供出院后的TOC电话对患者和医疗团队都有好处,同时为药学学生在毕业前提供宝贵的学习经验。
{"title":"Impact of Student Pharmacist-Led Transition-of-Care Services on 30-Day Hospital Readmissions at a University Call Center.","authors":"Huy Pham, Tricia Gangoo-Dookhan, Genevieve Hale, Alexandra Perez, Tina Joseph","doi":"10.1177/87551225231187832","DOIUrl":"10.1177/87551225231187832","url":null,"abstract":"<p><p><b>Background:</b> Transition of care (TOC) refers to the movement of patients between different health care settings due to changes in medical conditions and needs. Pharmacists can play an important role in TOC services as polypharmacy is a common reason for hospital readmission that costs the US taxpayers an average of $17 billion annually. <b>Objective:</b> The purpose of this study is to evaluate the impact of TOC telehealth services provided by pharmacy students at a university-based call center on 30-day hospital readmission. <b>Methods:</b> In this retrospective observational study, an electronic chart review was conducted for patients who were discharged from the hospital and received a telephone call from pharmacy students. Patients were referred to the pharmacy team from a primary care provider office. The co-primary endpoints were the number of 30-day all-cause hospital readmissions (including emergency department visits) and 30-day readmission due to initial admission diagnosis in patients who received a telephonic TOC call from a pharmacy student compared with patients who declined or were unable to be reached. Types of pharmacy-related TOC interventions provided by students were also collected. <b>Results:</b> A total of 84 patients were included in this study. All-cause 30-day readmission was similar between groups (13% vs 15.8%), whereas 30-day readmission due to initial admission diagnosis was much lower in the intervention group (5.9% vs 11.1%). Although a positive trend was observed in favor of the intervention group, a statistically significant difference was not observed for both 30-day all-cause readmission and 30-day readmission due to initial admission diagnosis. Medication reconciliation, adherence counseling, and lifestyle education (diet, exercise) are the most common topics discussed with the patients during TOC interventions. <b>Conclusion:</b> Using student pharmacists to provide postdischarge TOC calls can be a benefit to the patient and the health care team while offering pharmacy students valuable learning experience prior to graduation.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10515973/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41122896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Pharmacy Technology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1